“Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? – a pharmacoeconomic study” (2024) Headache Medicine, 15(Supplement), p. 98. Available at: https://headachemedicine.com.br/hm/article/view/1230 (Accessed: 22 January 2026).